Brief: Hansa Biopharma Says Hnsa-5487 Is A Next-Generation Igg-Cleaving Enzyme And Lead Candidate In NiceR Development Program
09/10/2023 16:36
Oct 9 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HNSA-5487 IS A NEXT-GENERATION IGG-CLEAVING ENZYME AND
LEAD
CANDIDATE IN NICER DEVELOPMENT PROGRAM
Source text for Eikon: ID:nWkrqpDvj
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS